Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2021 Filed May 6, 2021 16:28 UTC |
Griffiths GrahamChief Business Officer
|
PurchaseOrdinary Shares | 100 | $17.00 | $1,700.00 |
DisclosureSEC source: 0001104659-21-062432 · tm2115262-6_4seq1.xml · nonDerivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 16:28 UTC |
Wright RobinDirector
|
PurchaseOrdinary Shares | 14,000 | $17.00 | $238,000.00 |
DisclosureSEC source: 0001104659-21-062430 · tm2115262-5_4seq1.xml · nonDerivative · entry 1 Wright Robin · CIK 0001851640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,506 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 16:27 UTC |
Ellis ChristopherChief Operating Officer
|
PurchaseOrdinary Shares | 75 | $17.00 | $1,275.00 |
DisclosureSEC source: 0001104659-21-062427 · tm2115262-4_4seq1.xml · nonDerivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC |
Phillips Anne M.Director
|
PurchaseOrdinary Shares | 3,000 | $17.00 | $51,000.00 |
DisclosureSEC source: 0001104659-21-062424 · tm2115262-2_4seq1.xml · nonDerivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 16:29 UTC |
DAWES KAREN ADirector
|
PurchaseOrdinary Shares | 1,700 | $17.00 | $28,900.00 |
DisclosureSEC source: 0001104659-21-062434 · tm2115262-7_4seq1.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC |
Oxford Science Enterprises plc10% owner
|
ConversionSeries B preferred shares · Derivative | 1,661,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · derivative · entry 7 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,661,184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · shares: The number of shares reported reflects the conversion set out in Footnote (3). F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.exercise_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.expiration_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · derivative.underlying_shares: The number of shares reported reflects the conversion set out in Footnote (3). Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC |
Oxford Science Enterprises plc10% owner
|
ConversionSeries A redeemable convertible preferred shares · Derivative | 1,704,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · derivative · entry 6 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,704,444 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · shares: The number of shares reported reflects the conversion set out in Footnote (3). F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.exercise_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.expiration_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · derivative.underlying_shares: The number of shares reported reflects the conversion set out in Footnote (3). Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC |
Oxford Science Enterprises plc10% owner
|
ConversionOrdinary Shares · Derivative | 4,832,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · derivative · entry 5 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,832,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · shares: The number of shares reported reflects the conversion set out in Footnote (3). F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.exercise_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F3 · derivative.expiration_date: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. F4 · derivative.underlying_shares: The number of shares reported reflects the conversion set out in Footnote (3). Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC |
Oxford Science Enterprises plc10% owner
|
PurchaseAmerican Depositary Shares | 600,000 | $17.00 | $10,200,000.00 |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · nonDerivative · entry 4 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,797,770 F2 · security: Each American Depositary Share represents one ordinary share. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC |
Oxford Science Enterprises plc10% owner
|
ConversionOrdinary Shares | 1,661,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · nonDerivative · entry 3 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,197,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share. F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC |
Oxford Science Enterprises plc10% owner
|
ConversionOrdinary Shares | 1,704,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · nonDerivative · entry 2 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,536,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share. F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC |
Oxford Science Enterprises plc10% owner
|
ConversionOrdinary Shares | 4,832,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-062421 · tm2115262-1_4seq1.xml · nonDerivative · entry 1 Oxford Sciences Innovation plc · CIK 0001856079 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,832,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share. F3 · price: Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date. Read SEC document |
| May 04, 2021 Filed May 7, 2021 21:24 UTC Amendment |
Enright WilliamDirector · Chief Executive Officer
|
GrantOrdinary Shares | 514,923 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-063196 · tm2115637-1_4aseq1.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,258,377 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 514,923 RSUs. F2 · price: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 514,923 RSUs. Read SEC document |
| April 30, 2021 Filed May 3, 2021 19:20 UTC |
M&G INVESTMENT MANAGEMENT LTD10% owner
|
PurchaseAmerican Depositary Shares | 125,000 | $14.40 | $1,800,000.00 |
DisclosureSEC source: 0001567619-21-008855 · doc1.xml · nonDerivative · entry 1 M&G INVESTMENT MANAGEMENT LTD · CIK 0000922898 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Please see footnote Disclosed balance after: 1,088,597 F1 · security: Each representing one ordinary share. F2 · ownership.nature: The reported securities are held directly by M&G ACS, advised by M&G Investment Management Limited. The reported securities may be deemed beneficially owned for the purposes of Section 13(d) of the Securities Exchange Act 1934 by M&G Investment Management Limited as investment manager to these funds. The Reporting Person disclaims beneficial ownership of the securities for purposes of Rule 16a-1(a)(2) and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:27 UTC |
Scheeren JosephDirector
|
GrantShare Option (Right to Buy) · Derivative | 34,328 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061228 · tm2114558-24_4seq1.xml · derivative · entry 1 Scheeren Joseph · CIK 0001852070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,328 Underlying: Ordinary Shares · 34,328 shares Expires 2031-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:23 UTC |
Griffiths GrahamChief Business Officer
|
GrantShare Option (Right to Buy) · Derivative | 88,065 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061221 · tm2114558-17_4seq1.xml · derivative · entry 2 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,065 Underlying: Ordinary Shares · 88,065 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:23 UTC |
Griffiths GrahamChief Business Officer
|
GrantShare Option (Right to Buy) · Derivative | 6,054 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061221 · tm2114558-17_4seq1.xml · derivative · entry 1 Griffiths Graham · CIK 0001851630 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,054 Underlying: Ordinary Shares · 6,054 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:22 UTC |
Egorov GeorgyChief Financial Officer
|
GrantShare Option (Right to Buy) · Derivative | 149,865 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061217 · tm2114558-14_4seq1.xml · derivative · entry 2 Egorov Georgy · CIK 0001851623 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,865 Underlying: Ordinary Shares · 149,865 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:22 UTC |
Egorov GeorgyChief Financial Officer
|
GrantShare Option (Right to Buy) · Derivative | 6,918 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061217 · tm2114558-14_4seq1.xml · derivative · entry 1 Egorov Georgy · CIK 0001851623 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,918 Underlying: Ordinary Shares · 6,918 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:25 UTC |
Hammacher AlexDirector
|
GrantShare Option (Right to Buy) · Derivative | 34,328 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061225 · tm2114558-21_4seq1.xml · derivative · entry 1 Hammacher Alex · CIK 0001851633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,328 Underlying: Ordinary Shares · 34,328 shares Expires 2031-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:24 UTC |
Marshall MargaretChief Medical Officer
|
GrantShare Option (Right to Buy) · Derivative | 225,570 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061222 · tm2114558-18_4seq1.xml · derivative · entry 2 Marshall Margaret · CIK 0001851634 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,570 Underlying: Ordinary Shares · 225,570 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:24 UTC |
Marshall MargaretChief Medical Officer
|
GrantShare Option (Right to Buy) · Derivative | 7,783 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061222 · tm2114558-18_4seq1.xml · derivative · entry 1 Marshall Margaret · CIK 0001851634 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,783 Underlying: Ordinary Shares · 7,783 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:26 UTC |
Morgon Pierre A.Director
|
GrantShare Option (Right to Buy) · Derivative | 34,328 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061226 · tm2114558-22_4seq1.xml · derivative · entry 1 Morgon Pierre A. · CIK 0001851636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,328 Underlying: Ordinary Shares · 34,328 shares Expires 2031-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:28 UTC |
Wright RobinDirector
|
GrantShare Option (Right to Buy) · Derivative | 34,328 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061229 · tm2114558-25_4seq1.xml · derivative · entry 1 Wright Robin · CIK 0001851640 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,328 Underlying: Ordinary Shares · 34,328 shares Expires 2031-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:22 UTC |
Ellis ChristopherChief Operating Officer
|
GrantShare Option (Right to Buy) · Derivative | 97,335 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061218 · tm2114558-15_4seq1.xml · derivative · entry 2 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,335 Underlying: Ordinary Shares · 97,335 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:22 UTC |
Ellis ChristopherChief Operating Officer
|
GrantShare Option (Right to Buy) · Derivative | 5,708 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061218 · tm2114558-15_4seq1.xml · derivative · entry 1 Ellis Christopher · CIK 0001851664 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,708 Underlying: Ordinary Shares · 5,708 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:23 UTC |
Evans Thomas GeorgeChief Scientific Officer
|
GrantShare Option (Right to Buy) · Derivative | 364,620 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061219 · tm2114558-16_4seq1.xml · derivative · entry 2 Evans Thomas George · CIK 0001851686 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,620 Underlying: Ordinary Shares · 364,620 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:23 UTC |
Evans Thomas GeorgeChief Scientific Officer
|
GrantShare Option (Right to Buy) · Derivative | 6,942 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061219 · tm2114558-16_4seq1.xml · derivative · entry 1 Evans Thomas George · CIK 0001851686 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,942 Underlying: Ordinary Shares · 6,942 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 5, 2021 00:26 UTC |
Phillips Anne M.Director
|
GrantShare Option (Right to Buy) · Derivative | 34,328 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061227 · tm2114558-23_4seq1.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,328 Underlying: Ordinary Shares · 34,328 shares Expires 2031-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:25 UTC |
DAWES KAREN ADirector
|
GrantShare Option (Right to Buy) · Derivative | 34,328 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061224 · tm2114558-20_4seq1.xml · derivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,328 Underlying: Ordinary Shares · 34,328 shares Expires 2031-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 5, 2021 00:24 UTC |
Enright WilliamDirector · Chief Executive Officer
|
GrantShare Option (Right to Buy) · Derivative | 176,130 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061223 · tm2114558-19_4seq1.xml · derivative · entry 2 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,130 Underlying: Ordinary Shares · 176,130 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 5, 2021 00:24 UTC |
Enright WilliamDirector · Chief Executive Officer
|
GrantOrdinary Shares | 455,775 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-061223 · tm2114558-19_4seq1.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199,229 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 455,775 RSUs. F2 · price: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 455,775 RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.